| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f06161c8222218d91d43831cf9cc228 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4708 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86762a649757905122fa9e61d0c78b30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27339a9b300753cbb9411413376fb8ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_972fdcaa037884f187cc122eb32fb6ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f7935ec5c0365035d8018fca732300a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_162e90db142e653c9f430ab3d68ac3db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e2c9da49bcade0c51bcb2f7f8cc1cdb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9906f88d06bc50bec21acc9812f6afff |
| publicationDate |
2022-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022232141-A1 |
| titleOfInvention |
Microdystrophin gene therapy administration for treatment of dystrophinopathies |
| abstract |
Provided are methods of treating or ameliorating the symptoms of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy by administration of therapeutically effective doses of recombinant adeno-associated viruses (rAAV) containing a transgene encoding a microdystrophin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023178053-A1 |
| priorityDate |
2021-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |